Redhill Biopharma is a drug manufacturers - specialty & generic business based in the US. Redhill Biopharma shares (RDHL) are listed on the NASDAQ and all prices are listed in US Dollars. Redhill Biopharma employs 53 staff and has a trailing 12-month revenue of around $6.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.38 |
|---|---|
| 52-week range | $0.26 - $3.28 |
| 50-day moving average | $0.41 |
| 200-day moving average | $0.65 |
| Wall St. target price | $760.00 |
| PE ratio | 0.0908 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $4.00 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.38 from 2024-07-25
| 1 week (2024-07-19) | 4.60% |
|---|---|
| 1 month (2024-06-27) | 0.74% |
| 3 months (2024-04-26) | -11.21% |
| 6 months (2024-01-26) | -44.13% |
| 1 year (2023-07-27) | -68.85% |
|---|---|
| 2 years (2022-07-27) | -53.55% |
| 3 years (2021-07-27) | 6.33 |
| 5 years (2019-07-26) | 6.97 |
Valuing Redhill Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Redhill Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Redhill Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Redhill Biopharma shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $6.5 million |
|---|---|
| Gross profit TTM | $45.3 million |
| Return on assets TTM | -15.71% |
| Return on equity TTM | -884.29% |
| Profit margin | 366.25% |
| Book value | $0.11 |
| Market Capitalization | $11.6 million |
TTM: trailing 12 months
We're not expecting Redhill Biopharma to pay a dividend over the next 12 months.
Redhill Biopharma's shares were split on a 1:40 basis on 22 March 2023. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Redhill Biopharma shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Redhill Biopharma shares which in turn could have impacted Redhill Biopharma's share price.
Over the last 12 months, Redhill Biopharma's shares have ranged in value from as little as $0.257 up to $3.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Redhill Biopharma's is 3.627. This would suggest that Redhill Biopharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
RedHill Biopharma Ltd. , a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. .
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.